Abstract
To evaluate the long-term cost-effectiveness of liraglutide compared with insulin glargine in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy from China’s health care system perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
